In patients with ALK-positive NSCLC, the ALK inhibitor crizotinib resulted in significant higher rates of response with an objective response rate (ORR) of 74% and a median progression-free survival (PFS) of 10.9 months than chemotherapy [3]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.